Studies have shown that IL-6, a proinflammatory cytokine increased in COVID-19 patients, inhibits the expression and activity of hepatic CYP isoenzymes, resulting in increased levels of drugs such as HCQ, CQ and remdesivir [56]. This evidence concerns the gene IL6 and COVID-19.